Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.12. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VWO | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $61.24 |
52-Week Low | $0.53 | $49.54 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $58.79, down 1.84% on the day amid a bearish technical signal. The fund's key financial ratios are not available in the data, but recent news highlights its low expense ratio of 0.06% and focus on emerging markets excluding South Korea, which has impacted performance relative to peers. Technical indicators show mixed signals with neutral oscillators and bearish moving averages.
The outlook for VWO is influenced by emerging market flows and geopolitical factors, with opportunities in diversification away from U.S. stocks but risks from China's economic drag and expense ratio comparisons with competitors like EEM. Investor sentiment is cautious due to regional tensions and allocation debates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
